Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

NCT02472418 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2018-05-22

No results posted yet for this study

Summary

Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.

Conditions

Interventions

DRUG

DFN-15 Dose A (treatment A)

DFN-15 Dose A administered

DRUG

DFN-15 Dose B (treatment B)

DFN-15 Dose B administered

OTHER

Placebo (treatment C)

Placebo administered

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-05
Primary Completion
2015-12-01
Completion
2016-05-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02472418 on ClinicalTrials.gov